MedTrace Logo

Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis

NCT00413660 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 509

Last updated 2013-01-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the effectiveness and safety, over 6 months, of 6 dose regimens of CP-690,550, combined with methotrexate, for the treatment of adults with active rheumatoid arthritis.

Conditions

  • Arthritis, Rheumatoid

Interventions

DRUG

CP-690,550

4 blinded tablets administered BID

DRUG

CP-690,550

4 blinded tablets administered BID

DRUG

CP-690,550

4 blinded tablets administered BID

DRUG

CP-690,550

4 blinded tablets administered BID

DRUG

CP-690,550

4 blinded tablets administered BID

DRUG

CP-690,550

Oral tablets

OTHER

placebo

Placebo

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2008-08-31
Completion
2008-08-31

Countries

  • United States
  • Argentina
  • Brazil
  • Bulgaria
  • Chile
  • Czechia
  • Hungary
  • Mexico
  • Poland
  • Slovakia
  • Spain
  • Sweden
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00413660 on ClinicalTrials.gov